Peter Langmuir, MD
Advertisement
Articles by Peter Langmuir, MD
eter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses the vandetanib clinical trials.
Advertisement
Latest Updated Articles
Dr. Langmuir Discusses Vandetanib Clinical TrialsMarch 15th 2011
Dr. Langmuir Explains the Side Effects of VandetanibApril 7th 2011
Vandetanib Advantages in Medullary Thyroid CancerMarch 15th 2011
Dr. Langmuir on Vandetanib in Medullary Thyroid CancerMarch 15th 2011
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
The OncFive: Top Oncology Articles for the Week of 7/19
5